What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical evidence from two Phase 3 randomized controlled trials (TENAYA and LUCERNE) indicates that faricimab is moderately effective compared to aflibercept, with a mean change in best corrected visual acuity showing a difference of 0.4 letters. While this suggests a benefit, the margin of improvement is modest, thus justifying a rating of A.
Does the economic case hold at the expected price? — Cost effectiveness
The cost comparison indicates that faricimab is likely to be cost-saving or have similar costs compared to aflibercept and ranibizumab. The committee acknowledged that the total cost associated with faricimab is similar or lower, supporting a rating of A for marginal cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
The document does not provide specific data on HRQoL outcomes related to faricimab. While it mentions similar effectiveness to existing treatments, the absence of detailed patient-reported outcomes or validated tools leads to a rating of B++ due to minimal or mixed impact.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The evidence suggests that faricimab has a similar safety profile to aflibercept and ranibizumab, with similar adverse events reported. This acceptable safety profile, with no significant concerns raised, justifies a rating of A.
Was the drug compared against what payers expect? — Comparator Selection
The comparators selected (aflibercept and ranibizumab) are appropriate and recommended by NICE for the same condition. The committee concluded that these are suitable comparators, leading to a rating of A+.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative population of adults with wet age-related macular degeneration, and the criteria for treatment align with those for existing therapies. This moderate representativeness supports a rating of A.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Faricimab can be integrated into existing treatment pathways with minor adjustments, as it is an anti-VEGF injection similar to aflibercept and ranibizumab. This manageable integration supports a rating of A+.
Are the wider system costs understood? — Resource Use and Cost Implications
The document indicates that faricimab may reduce the number of injections and monitoring visits, suggesting a favorable resource use profile. This potential for cost savings aligns with a rating of A.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is derived from two Phase 3 RCTs with a substantial sample size (1,329 adults), indicating strong robustness. Minor limitations were noted, but overall, the evidence quality supports a rating of A+.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is some uncertainty regarding the long-term efficacy and the number of injections needed beyond the initial treatment period. This uncertainty, while manageable, leads to a rating of B++.
